Page last updated: 2024-11-05

troglitazone and Allergy, Drug

troglitazone has been researched along with Allergy, Drug in 2 studies

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Research Excerpts

ExcerptRelevanceReference
"Troglitazone was the first thiazolidinedione antidiabetic agent approved for clinical use in 1997, but it was withdrawn from the market in 2000 due to serious idiosyncratic hepatotoxicity."2.46Troglitazone. ( Yokoi, T, 2010)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Yokoi, T1
Ikeda, T1

Reviews

2 reviews available for troglitazone and Allergy, Drug

ArticleYear
Troglitazone.
    Handbook of experimental pharmacology, 2010, Issue:196

    Topics: Biotransformation; Chemical and Drug Induced Liver Injury; Chromans; Drug Hypersensitivity; Humans;

2010
[Drug-induced liver injury].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2006, Volume: 127, Issue:6

    Topics: Acetaminophen; Anesthetics, General; Animals; Benzoquinones; Chemical and Drug Induced Liver Injury;

2006